EffusionNCT07003204
Neutrophil-to Lymphocyte and Monocyte-to-Lymphocyte Ratios in Exudative Pleural Effusion
An observational study of Effusion, run by Alexandria University at 1 site in Egypt.
Trial summary
Exudative pleural effusion (EPE) presents a diagnostic challenge, requiring accurate biomarkers to predict outcomes and guide treatment. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in pleural fluid are emerging as potential prognostic markers. Read more about this study
- Who is it for?
- Ages 18 months and older
- Conditions the study is for
- Effusion
- What is being tested?
- medical thoracoscopy
- Type of treatment
- Surgery or procedure
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 11 May 2025to 26 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 60 person with pleural effusion
Who may be able to join
- adult patients aged 18-80 years with an EPE diagnosis confirmed by thoracentesis.
Who cannot join
- Exclusion criteria included patients with a history of recent surgery, corticosteroid use, or those with mixed effusion types.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Diagnostic and Prognostic Role of Pleural Fluid Neutrophil-to Lymphocyte and Monocyte-to-Lymphocyte Ratios in Exudative Pleural Effusion
Exudative pleural effusion (EPE) presents a diagnostic challenge, requiring accurate biomarkers to predict outcomes and guide treatment. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in pleural fluid are emerging as potential prognostic markers. We aimed to assess the diagnostic and prognostic utility of pleural fluid NLR and MLR in EPE.
Read the detailed description
Pleural fluid NLR and MLR are reliable biomarkers for diagnosing malignant pleural effusion and predicting poorer survival outcomes. These ratios may be useful in clinical practice, especially in resource-limited settings, to guide decision-making in the management of pleural effusions.
- Conditions
- Effusion
- Being tested
- medical thoracoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
medical thoracoscopyProcedure or surgery
pleural fluid aspiration and cellular analysis
| Study group | Role | What they receive |
|---|---|---|
| only one group of patients | prospective cohort randomized control study Receives: Procedure: medical thoracoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
MLR and NLR measuring in pleural fluid
counting pleural fluid monocytes,lymphocytes and neutrophils
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2025
- Study start11 May 2025
- Primary completion25 May 2025
- Study completion26 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EffusionStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Sabry, Alexandria University
- Investigators
- mohamed Sabry eltarhony, lecturer, Principal investigator, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07003204
- Sponsor's protocol ID
- lymphocyte- monocyte- exudate
- Status last verified
- May 2025
- First submitted
- 26 May 2025
- Last updated
- 4 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: not in the policy of the department
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic and Prognostic Role of Pleural Fluid Neutrophil-to Lymphocyte and Monocyte-to-Lymphocyte Ratios in Exudative Pleural Effusion
- ClinicalTrials.gov ID
- NCT07003204
- Acronym / sponsor ID
- lymphocyte- monocyte- exudate
- Conditions
- Effusion
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 11 May 2025 (actual)
- Primary completion
- 25 May 2025 (actual)
- Study completion
- 26 May 2025 (actual)
- First posted
- 4 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exudative pleural effusion (EPE) presents a diagnostic challenge, requiring accurate biomarkers to predict outcomes and guide treatment. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in pleural fluid are emerging as potential prognostic markers. We aimed to assess the diagnostic and prognostic utility of pleural fluid NLR and MLR in EPE.
Detailed description
Pleural fluid NLR and MLR are reliable biomarkers for diagnosing malignant pleural effusion and predicting poorer survival outcomes. These ratios may be useful in clinical practice, especially in resource-limited settings, to guide decision-making in the management of pleural effusions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| only one group of patients | – | Procedure: medical thoracoscopyprospective cohort randomized control study |
Who may qualify
- Ages
- 18 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 60 person with pleural effusion
Key inclusion criteria (1 listed)
- adult patients aged 18-80 years with an EPE diagnosis confirmed by thoracentesis.
Key exclusion criteria (1 listed)
- Exclusion criteria included patients with a history of recent surgery, corticosteroid use, or those with mixed effusion types.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| medical thoracoscopypleural fluid aspiration and cellular analysis | Procedure or surgery | only one group of patients |
Primary outcome
MLR and NLR measuring in pleural fluid
Time frame: 1 month
counting pleural fluid monocytes,lymphocytes and neutrophils
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2025.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8075197/Link provided by the sponsor.
- Individual participant dataSharing planned: No. not in the policy of the department
Related trials for Effusion
RecruitingPhase 1
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
RecruitingObservational study
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Coronary Artery Disease, Myocarditis
Recruiting
CLIKX® Tympanostomy Tube Delivery System for the Placement of Tympanostomy Tubes
Otitis Media, Otitis Media Chronic
Not yet recruiting
Short-term Application of Lactoferrin Ventilation Tubes
Otitis Media With Effusion (OME)
Not yet recruitingObservational study
Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
Malignant Pleural Effusions (Mpe), Lung Cancer (Diagnosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed Sabry eltarhony, lecturer principal investigator
Alexandria University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Effusion, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MLR and NLR measuring in pleural fluid (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2025.